Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1992 Feb;118(2):83–86. doi: 10.1007/BF01187497

Antiproliferative activity of the non-myelotoxic antitumour agent of plant origin, Thaliblastine, on two human glioma cell lines

D K Todorov 1, W J Zeller 2,✉
PMCID: PMC12200738  PMID: 1531227

Abstract

The antiproliferative activity of the non-myelotoxic antitumour agent of plant origin, Thaliblastine, on two human glioma cell lines is described. Thaliblastine was added once one day following start of culture; proliferation was monitored over 7 days. The anti-proliferative activity of Thaliblastine was strongly dependent on concentration and time of incubation. The ID50 of Thaliblastine in T406 and GW27 glioma lines was 5.1 μg/ml and 8.2 μg/ml (7.0 μM and 11.2 μM), respectively.

Key words: Thaliblastine, Antiproliferative activity, Human glioma cell lines

Abbreviation

TBL

Thaliblastine

References

  1. Allen L, Creaven P (1973) Inhibition of macromolecular biosynthesis in cultured L 1210 mouse leukemia cells by Thalicarpine (NSC-68075). Cancer Res 33:3112–3116 [PubMed] [Google Scholar]
  2. Arnaudov I, Georgiev G, Petrov M, Serbesova M (1986) The effect of the Bulgarian antineoplastic agent Thaliblastine in the treatment of patients with malignant lymphomas. 1st International Symposium on Clinical Pharmacology, Sofia. Abstract 13
  3. Broder L, Carter S (1971) Thalicarpine (NSC-68075). Clinical Brochure. National Cancer Institute, Bethesda, USA [Google Scholar]
  4. Christov I, Krusteva E (1983) Thaliblastine-potential plant antitumor agent. Phase I of clinical trial. Sovremenna Med 34:381–385 [Google Scholar]
  5. Christov I, Krusteva E (1985) Thaliblastine — a potential plant anti-tumor preparation. In: Eckhardt S, Kerpel-Fronius S (eds) CMEA — Chemotherapy Symposium, Akademiai Kiado, Budapest, pp 497–502
  6. Christov I, Krusteva E, Ognyanova V, Tanev S (1986) Thaliblastine — the I–II phase clinical trial. 14th International Cancer Congress Budapest. Abstract 452
  7. Creaven P, Allen L (1976) Thalicarpine (NSC-68075): plasma decay and urinary excretion in man. Cancer Treat Rep 60:69–75 [PubMed] [Google Scholar]
  8. Creaven P, Cohen M, Selawry D, Tejada F, Broder L (1975) Phase I study of Thalicarpine (NSC-68075), a plant alkaloid of novel structure. Cancer Chemother Rep 59:1001–1006 [PubMed] [Google Scholar]
  9. Deliconstantinos G, Ramantanis G, Todorov D (1983) Interaction of 99m Tc-labeled liposomes with Walker tumor cells in vitro. Liposome-mediated introduction of Thaliblastine into resistant Walker tumor cells. Gen Pharmacol 14:407–411 [DOI] [PubMed] [Google Scholar]
  10. Fischer H, Zeller WJ, Schwechheimer K, Hutter K-J, Wowra B, Kunze S, Sturm V (1989) Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice. Onkologie 12:169–174 [DOI] [PubMed] [Google Scholar]
  11. Freeman A, Fenstermacher J, Shapiro W, Kemshead J, Chasin M, Colvin O, Diksic M, Finley J, Hertler A, Levin V, Mayhew E, Poplack D, Shapiro J, Ushio Y (1990) Forbeck forum on improved drug delivery to brain tumours. Sel Cancer Therap 6:109–118 [DOI] [PubMed] [Google Scholar]
  12. Ilarionova M, Maneva K, Todorov D (1980) Pathomorphological studies on animals bearing experimental tumors treated with Thaliblastine. C R Acad Bulg Sci 33:719–722 [Google Scholar]
  13. Kornblith P, Walker M (1988) Chemotherapy of malignant gliomas. J Neurosurg 68:1–17 [DOI] [PubMed] [Google Scholar]
  14. Kupchan S, Chakravarti K, Yokoyoma N (1963) Thalicarpine, a new hypotensive alkaloid fromThalictrum dasycarpum. J Pharm Sci 52:985–988 [DOI] [PubMed] [Google Scholar]
  15. Kupchan S, Liepa A, Kameswaran V, Sempuku K (1973) Total synthesis of the tumor-inhibitory alkaloid Thalicarpine. J Am Chem Soc 95:2995–3000 [DOI] [PubMed] [Google Scholar]
  16. Mircheva J, Stoychkov J (1976) Effect of Thaliblastine on transplantable tumors in mice. Biomed Exp 25:280–281 [PubMed] [Google Scholar]
  17. Mollov N, Dutschewska H, Panov P (1964) Über die Alkaloide vonThalictrum minus L. ssp. elatum bulgarischer Herkunft. C R Acad Bulg Sci 17:709–712 [Google Scholar]
  18. Mollov N, Dutschewska H, Siljanovska K, Stojcev S (1968) Cytotoxic effect of alkaloids fromThalictrum minus ssp. elatum and their derivatives. C R Acad Bulg Sci 21:605–608 [PubMed] [Google Scholar]
  19. Philips B (1974) A simple, small scale cytotoxicity test, and its uses in drug metabolism studies. Biochem Pharmacol 23:131–138 [DOI] [PubMed] [Google Scholar]
  20. Todorov D (1983) Pharmacological approaches to modifying the effects of some antitumor agents. Thesis D. Sc., Sofia
  21. Todorov D (1988) Thaliblastine. Drugs Future 13:234–238 [Google Scholar]
  22. Todorov D, Damyanova M (1975) Investigations into the acute toxicity of the antitumor alkaloid Thaliblastine. C R Acad Bulg Sci 28:709–711 [Google Scholar]
  23. Todorov D, Deliconstantinos G (1982) Incorporation of the antitumor alkaloid Thaliblastine in liposomes enhances its cytotoxic activity in vitro. Experientia 38:857–858 [DOI] [PubMed] [Google Scholar]
  24. Tomita M, Furukawa H, Lu S, Kupchan S (1965) The constitution of Thalicarpine. Tetrahedron Lett 48:4309–4316 [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES